ELSEVIER

European Journal of Pharmacology
Molecular Pharmacology Section 269 (1994) 385–388

ejp
molecular pharmacology

Author index

Adachi, M., Furuichi, Y. and Miyamoto, C.
Identification of a region of the human endothelin ET_A receptor required for interaction with bosentan (269) 225
Adan, R.A.H., Oosterom, J., Ludvigsdottir, G., Brakkee, J.H., Burbach, J.P.H. and Gispen, W.H.
Identification of antagonists for melanocortin MC_3, MC_4 and MC_5 receptors (269) 331
Agbotounou, W.K., Umezawa, K., Jacquemin-Sablon, A. and Pierre, J.
Inhibition by two lavendustins of the tyrosine kinase activity of $pp60^{F527}$ in vitro and in intact cells (269) 1
Akishita, M., see Ishikawa, M. (269) 311
Akiyama, T., see Nakazawa, K. (269) 375
Ambrosio, C., see Roscetti, G. (269) 17
Amiranoff, B., see Heuillet, E. (269) 139
Amiranoff, B., see Lorinet, A.-M. (269) 59
Aramori, I., Morikawa, N., Zenkoh, J., O'Donnell, N., Iwami, M., Kojo, H., Notsu, Y., Okuhara, M., Ono, S. and Nakanishi, S.
Subtype- and species-selectivity of a tachykinin receptor antagonist, FK888, for cloned rat and human tachykinin receptors (269) 277
Audus, K.L., see Borges, N. (269) 243
Azevedo, I., see Borges, N. (269) 243

Barbaccia, M.L., see Roscetti, G. (269) 17
Barnes, P.J., see Mak, J.C.W. (269) 35
Baron, A., Rakotoarisoa, L., Leprêtre, N. and Mironneau, J.
Inhibition of L-type Ca^{2+} channels in portal vein myocytes by the enantiomers of oxodipine (269) 105
Baudry, M., see Marvizón, J.-C. (269) 165
Beart, P.M., Ryan, M.C., Mercer, L.D., Jarrott, B. and Wong, M.G.
Heterocyclic amino alcohols related to ifenprodil as σ receptor ligands: binding and conformational analyses (269) 193
Billecocq, A., Hedlund, P.B., Bolaños-Jiménez, F. and Fillion, G.
Characterization of galanin and 5-HT_{1A} receptor coupling to adenylyl cyclase in discrete regions of the rat brain (269) 209
Blanchard, J.-C., see Heuillet, E. (269) 139
Bolaños-Jiménez, F., see Billecocq, A. (269) 209
Bolger, M.B., see Hawkinson, J.E. (269) 157
Borden, L.A., Dhar, T.G.M., Smith, K.E., Weinshank, R.L., Branchek, T.A. and Gluchowski, C.
Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1 (269) 219
Borges, N., Shi, F., Azevedo, I. and Audus, K.L.
Changes in brain microvessel endothelial cell monolayer permeability induced by adrenergic drugs (269) 243
Bouaiche, Z., see Heuillet, E. (269) 139
Bouloumié, A., Valet, P., Daviaud, D., Prats, H., Lafontan, M. and Saulnier-Blache, J.-S.
Adipocyte α_{2A}-adrenoceptor is the only α_2-adrenoceptor regulated by testosterone (269) 95
Brakkee, J.H., see Adan, R.A.H. (269) 331
Branchek, T.A., see Borden, L.A. (269) 219
Bridges, R.J., see Miller, S. (269) 235
Browning, M.D., see Firestone, J.A. (269) 177
Burbach, J.P.H., see Adan, R.A.H. (269) 331
Burnett, J.P., see Sharp, R.L. (269) R5
Butt, E., Eigenthaler, M. and Genieser, H.-G.
(Rp)-8-pCPT-cGMPS, a novel cGMP-dependent protein kinase inhibitor (269) 265

Cavanni, P., Pinnola, V., Mugnaini, M., Trist, D., Van Amsterdam, F.Th.M. and Ferraguti, F.
Pharmacological analysis of carboxyphenylglycines at metabotropic glutamate receptors (269) 9
Chamberlin, A.R., see Miller, S. (269) 235
Chen, T.-S., see Koutsilieri, E. (269) R3
Chung, F.-Z., see Pinnock, R.D. (269) 73
Chung, F.-Z., see Suman-Chauhan, N. (269) 65
Classen, M., see Schepp, W. (269) 183
Cotman, C.W., see Miller, S. (269) 235
Craig, C.G., Temple, S.D. and White, T.D.
Is cyclic AMP involved in excitatory amino acid-evoked adenosine release from rat cortical slices? (269) 79
Crespo, A., see Heuillet, E. (269) 139

Daviaud, D., see Bouloumié, A. (269) 95
De Boer, T., see Stam, N.J. (269) 339
Dehne, K., see Schepp, W. (269) 183
Dhar, T.G.M., see Borden, L.A. (269) 219
Doble, A., see Heuillet, E. (269) 139
Drejer, J., see Verdoorn, T.A. (269) 43
Droogmans, G., see Gericke, M. (269) 381
Drukarch, B., see Vermeulen, R.J. (269) 121
Dubois, H., see Heuillet, E. (269) 139
Dugay, P., see Heuillet, E. (269) 139

Eigenthaler, M., see Butt, E. (269) 265
Eng, J., see Schepp, W. (269) 183
Eysselein, V.E., see Grandt, D. (269) 127

Fang, S., see Knapp, R.J. (269) 133
Ferraguti, F., see Cavanni, P. (269) 9
Feth, F., see Grandt, D. (269) 127
Fillion, G., see Billecocq, A. (269) 209
Filloux, F.M., Fitts, R.C., Skeen, G.A. and White, H.S.
The dihydropyridine nitrendipine inhibits [^{3}H]MK 801 binding to mouse brain sections (269) 325
Firestone, J.A., Marks, M.J., Gerhardt, G.A. and Browning, M.D.
ABT-200, a norepinephrine uptake inhibitor, blocks Ca^{2+} signals in chromaffin cells (269) 177
Fitts, R.C., see Filloux, F.M. (269) 325
Furuichi, Y., see Adachi, M. (269) 225

Gee, K.W., see Hawkinson, J.E. (269) 157
Genieser, H.-G., see Butt, E. (269) 265
George, S.R., see Ng, G.YK. (269) 349
George, S.R., see Ng, G.YK. (269) 365
Gerhardt, G.A., see Firestone, J.A. (269) 177
Gericke, M., Oike, M., Droogmans, G. and Nilius, B.
Inhibition of capacitative Ca^{2+} entry by a Cl^- channel blocker in human endothelial cells (269) 381
Gies, J.-P., see Lach, E. (269) 87
Gispen, W.H., see Adan, R.A.H. (269) 331
Gluchowski, C., see Borden, L.A. (269) 219
Goebell, H., see Grandt, D. (269) 127
Grandordy, B., see Mak, J.C.W. (269) 35
Grandt, D., Feth, F., Rascher, W., Reeve Jr., J.R., Schlicker, E., Schimiczek, M., Layer, P., Goebell, H., Eysselein, V.E. and Michel, M.C.
[Pro^{34}]peptide YY is a Y_1-selective agonist at peptide YY/neuropeptide Y receptors (269) 127
Grimson, P., see Suman-Chauhan, N. (269) 65
Guard, S., see Suman-Chauhan, N. (269) 65

Hamaguchi, A., see Ohta, K. (269) 115
Han, S.-z., see Ishikawa, M. (269) 311
Hawkinson, J.E., Kimbrough, C.L., McCauley, L.D., Bolger, M.B., Lan, N.C. and Gee, K.W.
The neuroactive steroid 3α-hydroxy-5β-pregnan-20-one is a two-component modulator of ligand binding to the $GABA_A$ receptor (269) 157
Hedlund, P.B., see Billecocq, A. (269) 209
Heuillet, E., Bouaiche, Z., Ménager, J., Dugay, P., Munoz, N., Dubois, H., Amiranoff, B., Crespo, A., Lavayre, J., Blanchard, J.-C. and Doble, A.
The human galanin receptor: ligand-binding and functional characteristics in the Bowes melanoma cell line (269) 139
Hietala, J., see Kuoppamäki, M. (269) 201
Hill, D.R., see Pinnock, R.D. (269) 73
Holst, J.J., see Schepp, W. (269) 183
Honda, K., see Saita, Y. (269) 249
Honma, Y., see Saita, Y. (269) 249
Hruby, V.J., see Knapp, R.J. (269) 133

Ikeda, U. and Shimada, K.
Nitric oxide release from rat aortic smooth muscle cells is not attenuated by angiotensin converting enzyme inhibitors (269) 319
Imanishi, N., see Koike, H. (269) 299
Inoue, K., see Nakazawa, K. (269) 375
Ishikawa, M., Ouchi, Y., Han, S.-z., Akishita, M., Kozaki, K., Toba, K., Namiki, A., Yamaguchi, T. and Orimo, H.
Parathyroid hormone-related protein reduces cytosolic free Ca^{2+} level and tension in rat aortic smooth muscle (269) 311
Iwami, M., see Aramori, I. (269) 277
Iwao, H., see Ohta, K. (269) 115

Jacquemin-Sablon, A., see Agbotounou, W.K. (269) 1
Jarrott, B., see Beart, P.M. (269) 193
Javoy-Agid, F., see Lorinet, A.-M. (269) 59
Johansen, T.H., see Verdoorn, T.A. (269) 43
Johansson, M.H. and Westlind-Danielsson, A.
Forskolin-induced up-regulation and functional supersensitivity of dopamine D_2long receptors expressed by Ltk^- cells (269) 149
Jones, S.B., see Zorn, S.H. (269) R1
Jongenelen, C.A.M., see Vermeulen, R.J. (269) 121

Kim, S., see Ohta, K. (269) 115
Kimbrough, C.L., see Hawkinson, J.E. (269) 157
Klomp, J., see Stam, N.J. (269) 339
Knapp, R.J., Malatynska, E., Peterson, P., Zalewska, T., Fang, S., Hruby, V.J., Smith, T.L. and Yamamura, H.I.
[*N*-Methylnorleucine-(28,31)]cholecystokinin-(26-33) (SNF 8702) activity at a cloned rat CCK_B receptor (269) 133
Koike, H., Imanishi, N., Natsume, Y. and Morooka, S.
Effects of platelet activating factor receptor antagonists on intracellular platelet activating factor function in neutrophils (269) 299
Kojima, I., see Mogami, H. (269) 293
Kojo, H., see Aramori, I. (269) 277
Koutsilieri, E., O'Callaghan, J.F.X., Chen, T.-S., Riederer, P. and Rausch, W.-D.
Selegiline enhances survival and neurite outgrowth of MPP^+-treated dopaminergic neurons (269) R3
Kozaki, K., see Ishikawa, M. (269) 311
Kuoppamäki, M., Seppälä, T., Syvälahti, E. and Hietala, J.
Regulation of serotonin 5-HT_{2C} receptors in the rat choroid plexus after acute clozapine treatment (269) 201

Laburthe, M., see Lorinet, A.-M. (269) 59
Lach, E., Trifilieff, A., Scherrer, D. and Gies, J.-P.
Association of guinea pig lung bombesin receptors with pertussis toxin-sensitive guanine nucleotide binding proteins (269) 87
Lafontan, M., see Bouloumié, A. (269) 95
Lan, N.C., see Hawkinson, J.E. (269) 157
Langeveld, C.H., see Vermeulen, R.J. (269) 121
Lavayre, J., see Heuillet, E. (269) 139
Layer, P., see Grandt, D. (269) 127
Lazarovici, P., see Rasouly, D. (269) 255
Leprêtre, N., see Baron, A. (269) 105
Liston, D.R., see Zorn, S.H. (269) R1
Lorinet, A.-M., Javoy-Agid, F., Laburthe, M. and Amiranoff, B.
Galanin receptors in human hypothalamus: biochemical and structural analysis (269) 59
Ludvigsdottir, G., see Adan, R.A.H. (269) 331

Madden, Z., see Pinnock, R.D. (269) 73
Madden, Z., see Suman-Chauhan, N. (269) 65
Mak, J.C.W., Grandordy, B. and Barnes, P.J.
High affinity [^{3}H]formoterol binding sites in lung: characterization and autoradiographic mapping (269) 35
Malatynska, E., see Knapp, R.J. (269) 133
Marks, M.J., see Firestone, J.A. (269) 177
Marvizón, J.-C. and Baudry, M.
Allosteric interactions and modulator requirement for NMDA receptor function (269) 165
Massotti, M., see Roscetti, G. (269) 17
Mayne, N.G., see Sharp, R.L. (269) R5
McCauley, L.D., see Hawkinson, J.E. (269) 157
Ménager, J., see Heuillet, E. (269) 139
Mercer, L.D., see Beart, P.M. (269) 193
Michel, M.C., see Grandt, D. (269) 127
Miller, S., Bridges, R.J., Chamberlin, A.R. and Cotman, C.W.
Pharmacological dissociation of glutamatergic metabotropic signal transduction pathways in cortical astrocytes (269) 235
Mironneau, J., see Baron, A. (269) 105
Miura, K., see Ohta, K. (269) 115
Miyamoto, C., see Adachi, M. (269) 225
Miyata, K., see Saita, Y. (269) 249
Miyazaki, J.-i., see Mogami, H. (269) 293
Mogami, H., Shibata, H., Nobusawa, R., Ohnota, H., Satou, F., Miyazaki, J.-i. and Kojima, I.
Inhibition of ATP-sensitive K^+ channel by a non-sulfonylurea compound KAD-1229 in a pancreatic β-cell line, MIN 6 cell (269) 293
Morikawa, N., see Aramori, I. (269) 277
Morooka, S., see Koike, H. (269) 299

Mugnaini, M., see Cavanni, P. (269) 9
Munoz, N., see Heuillet, E. (269) 139

Nakanishi, S., see Aramori, I. (269) 277
Nakazawa, K., Akiyama, T. and Inoue, K.
Block by apomorphine of acetylcholine receptor channels expressed in *Xenopus* oocytes (269) 375
Namiki, A., see Ishikawa, M. (269) 311
Natsume, Y., see Koike, H. (269) 299
Ng, G.YK. and George, S.R.
Dopamine receptor agonist reduces ethanol self-administration in the ethanol-preferring C57BL/6J inbred mouse (269) 365
Ng, G.YK., O'Dowd, B.F. and George, S.R.
Genotypic differences in brain dopamine receptor function in the DBA/2J and C57BL/6J inbred mouse strains (269) 349
Nielsen, E.Ø., see Verdoorn, T.A. (269) 43
Nilius, B., see Gericke, M. (269) 381
Nishida, A., see Saita, Y. (269) 249
Nobusawa, R., see Mogami, H. (269) 293
Notsu, Y., see Aramori, I. (269) 277

O'Callaghan, J.F.X., see Koutsilieri, E. (269) R3
O'Donnell, N., see Aramori, I. (269) 277
O'Dowd, B.F., see Ng, G.YK. (269) 349
Ohnota, H., see Mogami, H. (269) 293
Ohta, K., Kim, S., Hamaguchi, A., Yukimura, T., Miura, K., Takaori, K. and Iwao, H.
Role of angiotensin II in extracellular matrix and transforming growth factor-β1 expression in hypertensive rats (269) 115
Oike, M., see Gericke, M. (269) 381
Okuhara, M., see Aramori, I. (269) 277
Olijve, W., see Stam, N.J. (269) 339
Ono, S., see Aramori, I. (269) 277
Oosterom, J., see Adan, R.A.H. (269) 331
Orimo, H., see Ishikawa, M. (269) 311
Ouchi, Y., see Ishikawa, M. (269) 311

Peterson, P., see Knapp, R.J. (269) 133
Pierre, J., see Agbotounou, W.K. (269) 1
Pinnock, R., see Suman-Chauhan, N. (269) 65
Pinnock, R.D., Suman-Chauhan, N., Chung, F.-Z., Webdale, L., Madden, Z., Hill, D.R. and Woodruff, G.N.
Characterization of tachykinin mediated increases in $[Ca^{2+}]_i$ in Chinese hamster ovary cells expressing human tachykinin NK_3 receptors (269) 73
Pinnola, V., see Cavanni, P. (269) 9
Prats, H., see Bouloumié, A. (269) 95

Qin, Z.-H. and Weiss, B.
Dopamine receptor blockade increases dopamine D_2 receptor and glutamic acid decarboxylase mRNAs in mouse substantia nigra (269) 25

Rakotoarisoa, L., see Baron, A. (269) 105
Rascher, W., see Grandt, D. (269) 127
Rasouly, D. and Lazarovici, P.
Staurosporine induces tyrosine phosphorylation of a 145 kDa protein but does not activate gp140^{trk} in PC12 cells (269) 255
Raufman, J.-P., see Schepp, W. (269) 183
Rausch, W.-D., see Koutsilieri, E. (269) R3
Reeve Jr., J.R., see Grandt, D. (269) 127
Regunathan, S. and Reis, D.J.
Effects of moxonidine, an imidazoline antihypertensive agent, on second messenger systems in rat brain (269) 273
Reis, D.J., see Regunathan, S. (269) 273
Riedel, T., see Schepp, W. (269) 183
Riederer, P., see Koutsilieri, E. (269) R3
Roscetti, G., Ambrosio, C., Trabucchi, M., Massotti, M. and Barbaccia, M.L.
Modulatory mechanisms of cyclic AMP-stimulated steroid content in rat brain cortex (269) 17
Ryan, M.C., see Beart, P.M. (269) 193

Saita, Y., Yazawa, H., Honma, Y., Nishida, A., Miyata, K. and Honda, K.
Characterization of YM022: its CCK_B/gastrin receptor binding profile and antagonism to CCK-8-induced Ca^{2+} mobilization (269) 249
Satou, F., see Mogami, H. (269) 293
Saulnier-Blache, J.-S., see Bouloumié, A. (269) 95
Schepp, W., Schmidtler, J., Riedel, T., Dehne, K., Schusdziarra, V., Holst, J.J., Eng, J., Raufman, J.-P. and Classen, M.
Exendin-4 and exendin-(9–39)NH_2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7–36)NH_2 (269) 183
Scherrer, D., see Lach, E. (269) 87
Schiele, J.O. and Schwabe, U.
Characterization of the adenosine receptor in microvascular coronary endothelial cells (269) 51
Schimiczek, M., see Grandt, D. (269) 127
Schlicker, E., see Grandt, D. (269) 127
Schmidtler, J., see Schepp, W. (269) 183
Schusdziarra, V., see Schepp, W. (269) 183
Schwabe, U., see Schiele, J.O. (269) 51
Seppälä, T., see Kuoppamäki, M. (269) 201
Sharp, R.L., Mayne, N.G. and Burnett, J.P.
Cyclothiazide differentially modulates human metabotropic glutamate receptors linked to phosphoinositide hydrolysis stimulation in oocytes (269) R5
Shi, F., see Borges, N. (269) 243
Shibata, H., see Mogami, H. (269) 293
Shibata, S., Tanaka, T. and Watanabe, S.
Facilitatory effects of somatostatin on reduced uptake of 2-deoxyglucose in cerebral cortical and hippocampal slices from aged rats (269) 269
Shimada, K., see Ikeda, U. (269) 319
Skeen, G.A., see Filloux, F.M. (269) 325
Smith, K.E., see Borden, L.A. (269) 219
Smith, T.L., see Knapp, R.J. (269) 133
Stam, N.J., Vanderheyden, P., Van Alebeek, C., Klomp, J., De Boer, T., Van Delft, A.M.L. and Olijve, W.
Genomic organisation and functional expression of the gene encoding the human serotonin 5-HT_{2C} receptor (269) 339
Stoof, J.C., see Vermeulen, R.J. (269) 121
Suman-Chauhan, N., Grimson, P., Guard, S., Madden, Z., Chung, F.-Z., Watling, K., Pinnock, R. and Woodruff, G.
Characterisation of [^{125}I][MePhe^7]neurokinin B binding to tachykinin NK_3 receptors: evidence for interspecies variance (269) 65
Suman-Chauhan, N., see Pinnock, R.D. (269) 73
Syvälahti, E., see Kuoppamäki, M. (269) 201

Takaori, K., see Ohta, K. (269) 115
Tanaka, T., see Shibata, S. (269) 269
Temple, S.D., see Craig, C.G. (269) 79
Toba, K., see Ishikawa, M. (269) 311
Trabucchi, M., see Roscetti, G. (269) 17
Trifilieff, A., see Lach, E. (269) 87
Trist, D., see Cavanni, P. (269) 9

Umezawa, K., see Agbotounou, W.K. (269) 1

Valet, P., see Bouloumié, A. (269) 95
Van Alebeek, C., see Stam, N.J. (269) 339

Van Amsterdam, F.Th.M., see Cavanni, P. (269) 9
Van Delft, A.M.L., see Stam, N.J. (269) 339
Vanderheyden, P., see Stam, N.J. (269) 339
Verdoorn, T.A., Johansen, T.H., Drejer, J. and Nielsen, E.Ø.
Selective block of recombinant glur6 receptors by NS-102, a novel non-NMDA receptor antagonist (269) 43
Vermeulen, R.J., Jongenelen, C.A.M., Langeveld, C.H., Wolters, E.Ch., Stoof, J.C. and Drukarch, B.
Dopamine D_1 receptor agonists display a different intrinsic activity in rat, monkey and human astrocytes (269) 121

Ward, K.M., see Zorn, S.H. (269) R1
Watanabe, S., see Shibata, S. (269) 269
Watling, K., see Suman-Chauhan, N. (269) 65
Webdale, L., see Pinnock, R.D. (269) 73
Weinshank, R.L., see Borden, L.A. (269) 219
Weiss, B., see Qin, Z.-H. (269) 25
Westlind-Danielsson, A., see Johansson, M.H. (269) 149
White, H.S., see Filloux, F.M. (269) 325
White, T.D., see Craig, C.G. (269) 79
Wolters, E.Ch., see Vermeulen, R.J. (269) 121
Wong, M.G., see Beart, P.M. (269) 193
Woodruff, G., see Suman-Chauhan, N. (269) 65
Woodruff, G.N., see Pinnock, R.D. (269) 73

Yamaguchi, T., see Ishikawa, M. (269) 311
Yamamura, H.I., see Knapp, R.J. (269) 133
Yazawa, H., see Saita, Y. (269) 249
Young, J.M., see Young, K.W. (269) 283
Young, K.W. and Young, J.M.
Potentiation by 1,4-dithiothreitol of histamine-induced inositol phosphate formation in rat cerebral cortex and human HeLa cells (269) 283
Yukimura, T., see Ohta, K. (269) 115

Zalewska, T., see Knapp, R.J. (269) 133
Zenkoh, J., see Aramori, I. (269) 277
Zorn, S.H., Jones, S.B., Ward, K.M. and Liston, D.R.
Clozapine is a potent and selective muscarinic M_4 receptor agonist (269) R1